Project Description

Lidasa

(dried powder for preparation of injection solution, U64) – Lydazum

international nonproprietary name

Hyaluronidase.

Ref

BP-0073

Pharmacotherapeutic group

Enzyme preparations.

Composition of the preparation

The drug contains hyaluronidase enzyme (64 units in 1 vial).

Pharmacological action

The active substance is hyaluronidase. Specific substrate of hyaluronidase is hyaluronic acid: the enzyme breaks the chain between С1 acetamidodeoxyglucose and С4 glucuronic acid. The drug reduces the viscosity of hyaluronic acid. It increases tissue permeability, improves their trophism, increases the elasticity of scary places, enhances the resorption of haematoma, eliminates contractions, increase articulation motion. It facilitates fluid diffusion in intratissue space (spreading factor). Hyaluronidase action is reversible: less its concentration, the viscosity of hyaluronic acid is recovered. S.c.injection: effectdurationis 48 h.

Indications 

Main indication for lidasa administration: articulation contracture, post-burn and post-intervention scars, ankylosing spondylitis, haematoma, scleroderma, traumatic injury of plexus and peripheral nerves (plexitits, neuritis), severe diseases of lumbar disks.

In ophthalmic practice lidasa is administered for thinner scarring of injured cornea areas. It is introduced in temple skin in case of retinopathy, in conjunctiva, retrabulbary, in vitreous body in case of hemorrhage.

Lidasa is administered as injections and inhalations in complex therapy to increase the concentration of antibacterial agents in lesion focus in patients with pulmonary tuberculosis of productive nature of inflammation.

Lidasa is also administered to aссelerate the absorption of medicines injected s.c. and i.m. (local anesthetics, miscle relaxants, isotonic solutions and others).

special indication

It is recommended to control regularly blood thyrotrophic hormone content, the higher level indicates insufficient drug dose. Suppressive thyroid therapy is evaluated also by radioactive iodine capture. In ancient multinodular goiter perform stimulating test with thyroid-tropin-releasing-hormone before treatment.

Mainly in hyperthyrosis restore metabolism gradually, in particular in elderly patients with cardiovascular pathology. In elderly patients the initial dose is NMT 50 mg.

Administer with care in stenocardia, hypertenisa, tachyarrythmia, epilepsy, insufficient adrenal cortex and hypophysis function, diabetes. In differentiated diagnostic test of thyroid suppression in patients with diabetes increase antidiabetic dose.

In children a very high initial dose may cause hepatic disorder. In children with convulsion attack possible increase of the attack recurrence.

In II and III pregnancy term the dose is usually increased by 25%. Administer with care in severe ancient hypo-function of thyroid gland. Eliminate eventual hypo-phase or hypothalamic hyperthyrosis before treatment.

In pregnancy and lactation drug intake is medically controlled. It is contraindicated in combination with thyroid static agents in pregnancy.

special warning

Not established

Dosage and method of administration

Lidasa is specially purified drug for parental (s.c. and i.m.) and inhalation intake. For injections dissolve the content of the vial in 1 ml of isotonic solution of sodium chloride or in 1ml of 0.5% of novocaine; for inhalation in 5 ml of isotonic solution of sodium chloride.

In therapy of articulation/scar contraction, ankylosing spondylitis, tendovaginitis, haematoma and others, introduce the ledasa solution (U64 in 1 ml) s.c. close to injury or in scar-abnormal tissue. Inject daily or in a day, the course is 6—10—15 and more injections. Therapeutic effect is manifested by scar softening, articulation mobility, elimination or reduction of contractions, haematoma resorbtion; the effect is mostly evident at the initial stages of the pathologic process.

In patients traumatic injury of plexus and peripheral nerves (brachial plexitis after bruise, traumatic mononeuritis and others), inject the drug s.c. in the injured nerve area (U64 in novocaine solution) in a day, the course is 12—15 injections. If necessary, repeat the course.

In patients with pulmonary tuberculosis of productive nature of inflammation administer lidasa inhalation daily, once day, 5 ml of the If necessary, repeat the course with an interval of 1.5—2 months. In addition, in this group of patients administer lidasa injections: 1 ml of the solution (U64) s.c. or i.m. daily or in a day. The course is10—20 injections.

overdosage

Symptoms: fever, nausea, vomit, vertigo, tachycardia, anesthetic and hypotenisa, local edema, erythema.

Treatment: injection of adrenalin, glycocorticoids, administration of antihistaminic.

safety measures

Perform test to hyaluronidase sensitivity before usage of the drug (s.c. 0.02 ml of the drug). Avoid lidasa injection in the area of infection, acute inflammation, tumor, administer with care in combination with other drugs (possible unpredictable enhancement of absorption and systematic effect). Avoidconcurrentadministrationwithestrogen. Inpregnancyandlactationadministerundervitalnecessityonly.

Side effects

The drug is usually well tolerated. In single cases possible allergic reaction, pain or infiltration in the area of the injection. Rare ventricular fibrillation under drug treatment.

Contraindications

Lidasa is contraindicated in individual hypersensitivity to the drug, malignant neoplasm, acute inflammation and infection, pulmonary hemorrhage an в hemoptysis, pulmonary tuberculosis with respiratory failure, the latest vitreous body hemerrhage.

Interactions with other medicinal preparations

Lidasa enhances drug absorption injected s.c, or i.m., and anesthesia of local anesthetics.

The form of release

Driedpowder (frozen-dried) forpreparationoftheinjectionsolutionU64 inglassvials.